XML 34 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies As of March 31, 2022, the Company had entered into commitments under the UMMS Agreement (see Note 3(A)) for which the Company provided notice of termination to UMMS of the UMMS Agreement in April 2022, which termination is expected to become effective by June 30, 2022 (see Note 14); the Services Agreements with certain of RSL's wholly owned subsidiaries (see Note 8(A)); and agreements to rent office and research and development laboratory spaces (see Note 5). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with 30- to 60-days' written notice, unless otherwise indicated. Further, certain of the Company's manufacturing agreements could require early termination and wind-down payments due from the Company as a result of the recent termination of its clinical trials. The Company had the right to terminate the UMMS Agreement at any time upon 90 days' advance written notice to UMMS. The Company had the right to terminate the Oxford Agreement at any time upon two months' advance written notice prior to the first commercial sale of a product.